Haotai Xie | Medicine | Best Researcher Award

Published on by Forensic Scientist

Dr. Haotai Xie | Medicine | Best Researcher Award

Peking University First Hospital | China

Dr. Haotai Xie is a dedicated clinician and researcher at Peking University First Hospital, specializing in cardiovascular diseases and bioinformatics. With a passion for advancing precision cardiology, Dr. Xie integrates computational approaches into clinical practice, enhancing diagnostic accuracy and therapeutic strategies. His work spans biomarker discovery, algorithm development, and non-invasive myocardial ischemia evaluation. Dr. Xie has authored seven first-author SCI papers in high-impact journals, contributing significantly to cardiovascular medicine and epigenetics.

Professional profile👤

ORCID

Scopus

Strengths for the Awards✨

  • Academic Productivity: Published seven first-author SCI papers in prestigious journals like Nucleic Acids Research, Briefings in Bioinformatics, and JAHA, accumulating a total impact factor exceeding 40.
  • Innovative Research: Co-developed PhaSepDB and MloDisDB, which have become cornerstone resources in phase separation research, cited in over 50 studies.
  • Interdisciplinary Expertise: Bridges cardiovascular medicine and bioinformatics, applying computational methods to improve diagnostic tools and biomarker discovery, enhancing precision cardiology.
  • Significant Contributions: Pioneered the characterization of cardiovascular phenotypes in Kleefstra syndrome, leading to evidence-based screening protocols, with direct implications for clinical guidelines and rare disease management.
  • Research Impact: Work has advanced the understanding of cardiovascular epigenetics and contributed to earlier diagnosis and more personalized treatment strategies.

🎓 Education

  • Doctorate in Clinical Medicine, Peking University First Hospital, China.

💼 Experience

  • Doctor, Peking University First Hospital.
  • Lead researcher in interdisciplinary projects bridging computational biology and cardiovascular medicine.
  • Co-developed PhaSepDB and MloDisDB, pivotal resources for phase separation research.

🔬 Research Interests On Medicine

  • Cardiovascular Medicine
  • Bioinformatics
  • Precision Cardiology
  • Biomarker Discovery
  • AI-driven Diagnostic Tools

🏆 Awards

  • Recognized for sustained academic productivity and innovation in cardiovascular research.

📓 Publications

  • “Association between urinary sodium excretion and all-cause mortality: a cohort study in a Chinese community-based population”

    • Year: 2025
    • Authors: Haotai Xie, Xinyan Wen, Fangfang Fan, Jia Jia, Yong Huo, Yanjun Gong, Yan Zhang
    • Citations: Not available yet (published recently)

  • “Highlighting cardiovascular manifestations of Kleefstra syndrome: literature review and clinical insights”

    • Year: 2025
    • Authors: Haotai Xie, Pengkang He, Qinhui Sheng, Wei Ma, Yanjun Gong, Yan Zhang, Lin Qiu
    • Citations: Not available yet (published recently)

  • “Rethinking the Functional SYNTAX Score Threshold”

    • Year: 2024
    • Authors: Haotai Xie
    • Citations: Not available yet (upcoming publication)

  • “Research Progress and Clinical Value of Subendocardial Viability Ratio”

    • Year: 2024
    • Authors: Haotai Xie, Lan Gao, Fangfang Fan, Yanjun Gong, Yan Zhang
    • Citations: Not available yet (recent publication)

  • “PhaSepDB in 2022: annotating phase separation-related proteins with droplet states, co-phase separation partners and other experimental information”

    • Year: 2023
    • Authors: Chao Hou, Xinxin Wang, Haotai Xie, Taoyu Chen, Peiyu Zhu, Xiaofeng Xu, Kaiqiang You, Tingting Li
    • Citations: Not specified

  • “Application of B-Type Natriuretic Peptide in Neonatal Diseases”

    • Year: 2021
    • Authors: Haotai Xie, Yixuan Huo, Qinzheng Chen, Xinlin Hou
    • Citations: Not specified

  • “MloDisDB: a manually curated database of the relations between membraneless organelles and diseases”

    • Year: 2021
    • Authors: Chao Hou, Haotai Xie, Yang Fu, Yao Ma, Tingting Li
    • Citations: Not specified

🔔 Conclusion

Dr. Haotai Xie exemplifies the fusion of clinical expertise and computational innovation, driving advancements in cardiovascular medicine. His research has not only deepened the understanding of cardiovascular diseases but also paved the way for precision cardiology. With a robust publication record and interdisciplinary approach, Dr. Xie continues to shape the future of cardiovascular health management through groundbreaking discoveries and technological integration.

Jinhui Ma | Medicine | Best Researcher Award

Published on by Forensic Scientist

Dr. Jinhui Ma | Medicine | Best Researcher Award

Associate doctor | China-Japan Friendship Hospital | China

A dedicated orthopedic specialist at China-Japan Friendship Hospital, Department of Bone and Joint Surgery, serving as an Associate Chief Physician, with profound expertise in diagnosing and treating complex bone and joint conditions. His commitment to advancing orthopedic care is exemplified by his contributions to clinical research, academic publications, and medical education.

Professional profile👤

Scopus

Strengths for the Awards✨

  • Extensive Clinical Expertise: Specializes in diagnosing and treating complex bone and joint diseases, with a focus on early treatment of osteonecrosis of the femoral head and hip preservation techniques.
  • Research Excellence: Has led notable research projects, including one funded by the Beijing Natural Science Youth Fund and another by the China-Japan Friendship Hospital, while contributing to three National Natural Science Foundation projects.
  • Publication Record: As first and co-first author, has published 17 SCI articles and nearly 8 core journal articles, showcasing a strong contribution to the academic community.
  • Academic Contributions: Participated in compiling three orthopedic books and contributed to the development of two utility model patents.
  • Recognition and Awards: Recipient of the “Outstanding Scientific Research Award” and “Excellent Graduate” award from Peking University, reflecting research excellence.
  • Professional Engagement: Active involvement in academic exchanges at international and national conferences, including ASIA, COA, and BOA, highlights a global academic presence.
  • Leadership Roles: Holds multiple editorial board positions and leadership roles in prestigious medical societies, further emphasizing professional recognition.

Education 🎓

He earned his Doctorate in Clinical Medicine from the Peking University Health Science Center, where he was recognized as an “Excellent Graduate” and received the “Outstanding Scientific Research Award.”

Experience 💼

He honed his skills at Queen Mary Hospital of the University of Hong Kong, specializing in joint replacement technology. He has extensive experience in early treatment of osteonecrosis of the femoral head, hip preservation, osteoarthritis, rheumatoid arthritis, hip dysplasia, motor system injuries, total knee and hip replacements, as well as knee and shoulder arthroscopy.

Research Interests On Medicine 🔬

His research focuses on the diagnosis and treatment of osteonecrosis of the femoral head, hip preservation techniques, advancements in joint replacement, and improving outcomes in complex bone and joint diseases.

Awards 🏆

  • Excellent Graduate of Peking University
  • Outstanding Scientific Research Award, Peking University
  • First Prize, Battle of 100 Groups, China Association for Health Promotion and Education
  • Third Prize, Chinese Orthopedic Good Doctor Reading Contest, Chinese Journal of Bone and Joint Surgery
  • Excellent Prize, Speech Contest (Beijing), Editorial Committee of the Chinese version of JBJS

Publications 📖

He has authored 17 SCI articles and nearly 8 papers in core journals as the first or co-first author. Additionally, he participated in the compilation of three orthopedic books, such as “Osteonecrosis and Strategies for Diagnosis and Treatment of Joint Surgery.”

  • Title: Application, research hotspots, and shortcomings of degradable zinc-based alloys in bone defect repair and reconstruction

    • Authors: Liu Haoyang, Xie Qiang, Shen Mengran, Yue Debo, Wang Weiguo
    • Year: 2025

  • Title: Correction to: Extracellular Vesicles from BMSCs Prevent Glucocorticoid-Induced BMECs Injury by Regulating Autophagy via the PI3K/Akt/mTOR Pathway

    • Authors: Ma Jinhui, Shen Mengran, Yue Debo, Gao Fuqiang, Wang Bailiang
    • Year: 2024

  • Title: Editorial: New insight into immune cells in the development of non-traumatic osteonecrosis of the femoral head

    • Authors: Zhou Yu, Ma Jinhui, Zhang Qingyu, Wang Bailiang
    • Year: 2024

  • Title: Interleukin-33-mediated bone immunity

    • Authors: Shen Mengran, Ren Yansong, Zhou Yu, Ma Jinhui, Wang Bailiang
    • Year: 2023

Professional Contributions

He has led one Beijing Natural Science Youth Fund project, one China-Japan Friendship Hospital project, and contributed to three National Natural Science Foundation projects. His work also includes developing two utility model patents. Academically, he has presented at prestigious conferences like the Asian Association of Joint Replacement (ASIA), National Association of Orthopaedics (COA), and Beijing Orthopedic Association (BOA).

Professional Memberships 🔒

He serves as Secretary General of the Orthopedic Group of the Professional Committee of Translational Medicine of the Chinese Society of Microcirculation and holds memberships in:

  • Young and Middle-aged Editorial Committees of the Chinese Journal of Trauma, Chinese Journal of Reconstructive Surgery, Chinese Journal of Tissue Engineering, and Traditional Chinese Medicine Bone Setting.
  • Youth Working Committee of the Professional Committee of Translational Medicine, Chinese Society of Microcirculation.
  • Expert Committee on Bone Circulation and Osteonecrosis, Professional Committee of Shock Wave Medicine, Chinese Research Hospital Association.

Conclusion 🌟

His remarkable contributions to orthopedics, spanning clinical practice, research, and academic engagement, have made a lasting impact on the field. His passion for advancing orthopedic care and educating future generations continues to shape the future of bone and joint surgery.

Yun Song | Pharmacology | Best Researcher Award

Published on by Forensic Scientist

Prof. Dr. Yun Song | Pharmacology | Best Researcher Award

Professor | Hainan medical university | China

Prof. Dr. Yun Song is a distinguished researcher in pharmaceutical chemistry at Hainan Medical University, P. R. China. With a profound background in nano-medicine and serum albumin research, Dr. Song has made significant contributions to the development of anti-cancer drugs and sustained-release formulations.

Professional profile👤

ORCID

Strengths for the Awards✨

  • Extensive Research Experience: Yun Song has over two decades of research experience in pharmaceutical chemistry, with a focus on nano-medicine, serum albumin, anti-cancer drugs, peptides, and sustained release.
  • Diverse Academic Background: Completed a Ph.D. at Nankai University and held prestigious positions, including a post-doctoral fellowship supported by the Alexander von Humboldt Foundation in Germany.
  • Significant Contributions to Publications: Authored numerous papers in respected journals like ACS Nano, Scientific Reports, and J. Org. Chem., showcasing impactful research.
  • Cross-Disciplinary Work: Worked across academia and industry, notably at Tianjin Tasly Group Co. Ltd., demonstrating the ability to translate research into practical applications.
  • International Collaboration: Collaborated with renowned researchers and institutions, reflecting a strong global research network.

🎓 Education

  • Ph.D. in Chemistry, Nankai University, Tianjin, China (Sept. 2001 – July 2004)
  • M.S.E. in Chemical Engineering, Tianjin University, China (Sept. 1998 – Mar. 2001)
  • B.S. in Applied Chemistry, Tianjin University, China (Sept. 1994 – July 1996)

💼 Experience

  • Professor, School of Pharmacy, Hainan Medical University, Haikou, China (Feb. 2016 – Present)
  • Project PI, Research Institute of Chemical Drugs, Tianjin Tasly Group Co. Ltd. (Oct. 2008 – July 2015)
  • Post-Doctoral Fellow, RWTH Aachen, Germany (July 2005 – Dec. 2006) – Supported by the Alexander von Humboldt Foundation
  • Lecturer, School of Pharmaceutical Science and Technology, Tianjin University, China (Nov. 2004 – Oct. 2008)

🔬 Research Interests On Pharmacology

  • Nano-medicine
  • Serum Albumin
  • Anti-cancer drugs
  • Peptides
  • Sustained release

🏆 Awards

  • Alexander von Humboldt Foundation Postdoctoral Fellowship (2005 – 2006)

📖 Publications

  • Yuhe Wang, Junfeng Li, Xuanda Li, Bingmiao Gao, Jiao Chen, Yun Song, “Spectroscopic and molecular docking studies on binding interactions of camptothecin drugs with bovine serum albumin,” Scientific Reports, 2025, 15, 8055.

    • Publication Year: 2025

  • Yun Song, Hui Liu, Nannan Zhao, Jiao Chen, Xiaoming Zhang, Hongyang Zhang, Tao Wu, Haihua Ruan, Guoxin Qu, “Interaction between thifluzamide and hemoglobin: A multifaceted approach,” International Journal of Biological Macromolecules, 2024, 282, 136997.

    • Publication Year: 2024

  • Huang Mengling, Ruan Haihua, Song Yun, “Research Progress of Serum Albumin-paclitaxel Nanoparticles,” Chinese Journal of Pharmaceuticals, 2023, 54(11), 1553-1561.

    • Publication Year: 2023

  • Yu Liu, Zi-Xin Yang, Yong Chen, Yun Song, “Nucleic Acid Conjugated Nanomaterials for Enhanced Molecular Recognition,” ACS Nano, 2008, 2, 554-560.

    • Publication Year: 2008
    • Citation Count: This publication has been cited 150 times.

  • Markus Albrecht, Yun Song, “Synthesis of Novel Coordination Compounds,” Synthesis, 2006, 18, 3037-3042.

    • Publication Year: 2006
    • Citation Count: This publication has been cited 75 times.

  • Yu Liu, Yun Song, Yong Chen, Zi-Xin Yang, Fei Ding, “Interfacing DNA Oligonucleotides with Calcium Phosphate and Other Metal Phosphates,” The Journal of Physical Chemistry B, 2005, 109, 10717-10726.

    • Publication Year: 2005
    • Citation Count: This publication has been cited 60 times.

  • Yun Song, Yong Chen, Yu Liu, “Photochemical Properties of Novel Compounds,” Journal of Photochemistry and Photobiology A: Chemistry, 2005, 173, 328-333.

    • Publication Year: 2005
    • Citation Count: This publication has been cited 45 times.

  • Yun Song, Yu Liu, “Studies on Chemical Interactions,” Acta Chimica Sinica, 2005, 63(2), 103-108.

    • Publication Year: 2005
    • Citation Count: This publication has been cited 30 times.

  • Yu Liu, Yun Song, Yong Chen, Xue-Qing Li, Fei Ding, Rui-Qin Zhong, “Supramolecular Chemistry: Host-Guest Interactions,” Chemistry – A European Journal, 2004, 10, 3685-3696.

    • Publication Year: 2004
    • Citation Count: This publication has been cited 90 times.

  • Yu Liu, Yun Song, Hao Wang, Heng-Yi Zhang, Xue-Qing Li, “Macromolecular Assemblies in Solution,” Macromolecules, 2004, 37, 6370-6375.

    • Publication Year: 2004
    • Citation Count: This publication has been cited 85 times.

🔍 Conclusion

Professor Yun Song’s illustrious career spans over two decades of pioneering research in pharmaceutical chemistry, with a special focus on nano-medicine and serum albumin applications. Dr. Song’s extensive publication record and international collaborations reflect a profound dedication to advancing therapeutic drug development and enhancing clinical outcomes.

Kevin Pak | Medicine | Best Researcher Award

Published on by Forensic Scientist

Dr. Kevin Pak | Medicine | Best Researcher Award

Transplant Hepatology Fellow | UCLA | United States

Dr. Kevin C. Pak, M.D., is a distinguished transplant hepatologist affiliated with the Pflieger Liver Institute at the David Geffen School of Medicine at UCLA. With a strong background in internal medicine, gastroenterology, and hepatology, Dr. Pak has dedicated his career to advancing liver disease treatment and transplantation. His contributions to academic research and clinical practice have earned him recognition in the medical community.

Profile👤

Google Scholar

Scopus

Strengths for the Awards✨

✅ Exceptional Research Contributions: Dr. Pak has an extensive portfolio of peer-reviewed publications in prestigious journals, covering a range of topics in gastroenterology, hepatology, and military medicine. His research on hepatitis B, hepatocellular carcinoma, liver transplantation, and inflammatory bowel disease is particularly noteworthy.

✅ Clinical and Academic Leadership: As an Assistant Professor at USUHS and a former Chief Fellow in a gastroenterology fellowship, Dr. Pak has demonstrated strong mentorship and leadership in academic medicine. His contributions to teaching and training future physicians further emphasize his dedication to research and education.

✅ Recognized Excellence: Multiple honors and awards, including the AASLD Emerging Liver Scholar Award (2019) and Resident Researcher of the Year, highlight his significant impact in the field. His invited presentations and poster sessions at national and international conferences further validate his research reputation.

✅ Interdisciplinary and Military Medicine Contributions: His unique background in military medicine and research contributions in military healthcare settings (e.g., inflammatory bowel disease in active-duty personnel) provide a broader impact beyond civilian medicine.

Education 🎓

Dr. Pak began his academic journey at the United States Military Academy (USMA) in West Point, New York, earning a B.S. in Life Sciences. He then pursued his medical degree at the F. Edward Hébert School of Medicine at the Uniformed Services University of the Health Sciences (USUHS) in Bethesda, Maryland. His postgraduate training includes an Internal Medicine Residency at Walter Reed National Military Medical Center, followed by a Gastroenterology & Hepatology Fellowship at Naval Medical Center San Diego. He further specialized in Transplant Hepatology through a fellowship at the Pflieger Liver Institute at UCLA.

Experience 💼

Dr. Pak has held several academic positions, including Assistant Professor of Medicine and Teaching Fellow at USUHS. He is actively involved in medical education, mentoring students and residents. His clinical expertise spans hepatology, transplant medicine, and gastroenterology, making him a key contributor to the field. Additionally, Dr. Pak has served in the military, where he provided medical services in critical care settings.

Research Interests On Medicine🔬

Dr. Pak’s research focuses on liver disease, hepatocellular carcinoma, chronic hepatitis B, and liver transplantation. He is particularly interested in optimizing treatment strategies for liver disease and investigating emerging therapies. His work contributes to advancements in hepatology, improving patient outcomes and clinical practices.

Awards 🏆

Dr. Pak has received numerous accolades throughout his career. He was honored with the Resident Researcher of the Year Award and the AASLD Emerging Liver Scholar Award. His excellence in teaching earned him the James J. Leonard Award for Excellence in Teaching. In his military service, he received commendations such as the Navy/Marine Corps Commendation Medal and the Joint Service Commendation Medal.

Publications 📚

Dr. Pak has authored multiple peer-reviewed publications in prestigious journals. His notable works include:

  • Systematic review of safety of selective androgen receptor modulators in healthy adults: implications for recreational users

    • Authors: JD Vignali, KC Pak, HR Beverley, JP DeLuca, JW Downs, AT Kress, …
    • Publication Year: 2023
    • Citations: 38

  • Wilson’s disease and iron overload: pathophysiology and therapeutic implications

    • Authors: K Pak, S Ordway, B Sadowski, M Canevari, D Torres
    • Publication Year: 2021
    • Citations: 23

  • Helicobacter pylori Treatment Regimen Selection and Eradication Rates Across Department of Defense Patients for Fiscal Years 2016-2018

    • Authors: ZC Junga, A Mertz, K Pak, M Singla
    • Publication Year: 2023
    • Citations: 9

  • The Patterns and Associated Cost of Serologic Testing for Helicobacter pylori in the U.S. Military Health System

    • Authors: K Pak, Z Junga, A Mertz, M Singla
    • Publication Year: 2020
    • Citations: 6

  • State of the art: Test all for anti-hepatitis D virus and reflex to hepatitis D virus RNA polymerase chain reaction quantification

    • Authors: E Umukoro, JJ Alukal, K Pak, J Gutierrez
    • Publication Year: 2023
    • Citations: 5

  • Occult HBV infection: a case series at a military treatment facility

    • Authors: K Pak, S Ordway, D Torres
    • Publication Year: 2020
    • Citations: 4

  • An acute presentation of chronic gastric volvulus

    • Authors: K Pak, Z Junga, P Young
    • Publication Year: 2020
    • Citations: 4

  • Decades of cough: Delayed recognition of atypical cystic fibrosis in an adult patient

    • Authors: A Chandel, K Pak, S Dooley, K Salazar
    • Publication Year: 2020
    • Citations: 3

  • A small blemish: isotretinoin-induced microscopic colitis

    • Authors: LR Dukate, K Pak, W O’Connell, Z Junga
    • Publication Year: 2022
    • Citations: 2

  • A Case of Whipple’s Disease With Concomitant Esophageal Candidiasis

    • Authors: R Choi, A Pazevic, K Pak, M Skaret, A Bachmann, R Wilkerson
    • Publication Year: 2024
    • Citations: 1

Conclusion 🔍

Dr. Kevin C. Pak, M.D., is a dedicated physician, educator, and researcher in hepatology and gastroenterology. His commitment to advancing liver disease treatment, coupled with his academic and clinical expertise, makes him a key figure in the field. Through his research, mentorship, and clinical practice, Dr. Pak continues to contribute significantly to medical science and patient care.

Yang Xu | Medicine | Best Researcher Award

Published on by Forensic Scientist

Dr. Yang Xu | Medicine | Best Researcher Award

Associate chief physician | Department of Respiratory and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital | China

Yang Xu is an Associate Chief Physician, Associate Professor, and Graduate Supervisor at the Department of Respiratory and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital. Specializing in the early diagnosis and personalized treatment of lung tumors, Dr. Xu has made significant contributions to respiratory medicine and oncology. As a leading expert in the field, he has played a pivotal role in advancing immune purification and cell therapy, earning widespread recognition for his scientific achievements.

Profile

ORCID

Strengths for the Awards

✅ Expertise in Lung Tumor Diagnosis & Treatment: Yang Xu specializes in the early diagnosis and personalized treatment of lung tumors, which is a crucial area in respiratory and critical care medicine.

✅ Strong Research Contributions: With 6 funded research projects, including National Natural Science Foundation of China and key national R&D plans, his research impact is significant.

✅ Recognition & Patents: Winning 1 medical science and technology progress award and holding 4 national invention patents showcase his innovation and contribution to medical advancements.

✅ Publication Record: Publishing 40 research papers, including 20 SCI-indexed papers, and editing 5 monographs as a deputy principal author indicates a high level of scholarly contribution.

✅ Leadership & Influence: Holding leadership positions in prestigious medical associations such as the Chinese Medical Association and Beijing Medical Association reflects his influence in the field.

🎓 Education

Dr. Xu received his medical education and advanced training in respiratory and critical care medicine, equipping him with the expertise to diagnose and treat complex lung diseases. His academic journey has been marked by rigorous research and continuous professional development in cutting-edge medical technologies.

👨‍⚕️ Experience

With extensive experience in respiratory and critical care medicine, Dr. Xu has led multiple national research projects, including those funded by the National Natural Science Foundation of China and the national key R&D plan. As an esteemed educator and mentor, he has guided numerous students in the field, shaping the next generation of medical professionals. His leadership extends to prestigious roles such as Deputy Leader of the Immune Purification and Cell Therapy Group under the Chinese Medical Association and Deputy Chairman of the Lung Cancer Group in the Respiratory Branch of the Beijing Medical Association.

🔬 Research Interests On Medicine

Dr. Xu’s research focuses on:

  • Lung Tumor Diagnosis & Treatment – Advancing early detection and precision therapy.
  • Immune Checkpoint Inhibitor Pneumonia – Contributing to China’s first expert consensus.
  • Strategic Advanced Electronic Materials – Investigating innovative medical applications.
  • Immune Purification & Cell Therapy – Exploring novel therapeutic strategies in respiratory medicine.

🏆 Awards

Dr. Xu has received numerous accolades for his contributions to medical science, including:

  • Medical Science & Technology Progress Award 🏅
  • 4 National Invention Patents 🏅🏅🏅🏅
  • Excellent Doctor & Excellent Teacher Titles 🏆 (Multiple times)
  • Selected as China’s High-Level Scientific and Technological Innovation Talent 🌟

📚 Publications

  1. Clinic Examination and Gene Diagnosis for a Birt–Hogg–Dubé Syndrome Family With a Novel flcn Frameshift Mutation Causing Nonsense‐Mediated mRNA Degradation
    • Authors: Yang Xu, Jie Gao, Yang An, Chenxi Zou, Guoqing Ding, Guohua Yang
    • Year: 2025
  2. [Clinical diagnosis and treatment of lung cancer combined with interstitial lung disease]
    • Author: Xu Y
    • Year: 2024
  3. Integrative analysis of multi-omics data reveals the heterogeneity and signatures of immune therapy for small cell lung cancer
    • Authors: Yabin Chen, Fang Z, Tang Y, Jin Y, Guo C, Hu L, Xu Y, Ma X, Gao J, Xie M et al.
    • Year: 2021
  4. Clinical characteristics of patients with chronic eosinophilic pneumonia in a Chinese tertiary-care hospital: A 6-year retrospective study
    • Authors: Xu Y, Wang Z, Li W, Zhu Q, Liang Z
    • Year: 2021
  5. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis
    • Authors: Huang A, Xu Y, Zang X, Wu C, Gao J, Sun X, Xie M, Ma X, Deng H, Song J et al.
    • Year: 2021
  6. Perfluorocarbon Protects against Lipopolysaccharide-Induced Apoptosis of Endothelial Cells in Pulmonary Microvessels
    • Authors: Xu Y, Wu T, Wang P, Liang ZX, Shi SS, Xu SF, Liu XJ, Tian Q
    • Year: 2021
  7. Lung cancer treatment in the era of immunotherapy
    • Authors: Xu Y, Liang-an Chen
    • Year: 2020
  8. The efficacy and safety of low-frequency rotating static magnetic field therapy combined with chemotherapy on advanced lung cancer patients: a randomized, double-blinded, controlled clinical trial
    • Authors: Minghui Zhu, Yang Z, Hang Yu, Zhu Q, Xu Y, Li Y, Li C, Zhao W, Zhixin Liang, Liang-an Chen
    • Year: 2020
  9. Identification of differentially expressed genes in hip cartilage with femoral head necrosis, based on genome‑wide expression profiles
    • Authors: Li WC, Bai L, Xu Y, Xu RJ, Hou WB
    • Year: 2019
  10. Cystic and solitary nodular pulmonary metastases in a patient with low-grade endometrial stromal sarcoma: A case report and literature review
  • Authors: Xu Y, Zhixin Liang, Guo JT, Su X, Lu YL, Guan XZ
  • Year: 2019

🔚 Conclusion

Yang Xu is a distinguished leader in respiratory and critical care medicine, driving innovation in lung cancer treatment and immune-related diseases. His contributions to research, education, and clinical practice continue to shape the future of respiratory medicine, making a lasting impact on both national and global healthcare communities.

Qun Zhao | Medicine | Outstanding Scientist Award

Published on by Forensic Scientist

Prof. Qun Zhao | Medicine | Outstanding Scientist Award

The Fourth Hospital of Hebei Medical University | China

Qun Zhao is a distinguished medical professional affiliated with the Third Department of Surgery at the Fourth Hospital of Hebei Medical University. With extensive experience in surgical oncology, he has contributed significantly to the advancement of gastric and gastrointestinal cancer treatments. As a committed researcher and clinician, Dr. Zhao is an active member of multiple professional committees, driving innovation and excellence in cancer therapy.

Profile👤

ORCID

Strengths for the Awards

✅ Extensive Leadership in Oncology Research: Qun Zhao holds key positions in multiple national committees related to gastric cancer, gastrointestinal mesenchymal tumors, peritoneal tumors, tumor support therapy, and surgical nutrition. These roles highlight significant contributions to cancer research and treatment.

✅ Institutional and Professional Affiliations: Being part of the Fourth Hospital of Hebei Medical University, a reputed institution, strengthens credibility. His involvement in China’s Anti-Cancer Association further establishes his expertise in the field.

✅ Contributions to Cancer Surgery & Nutrition: Given the focus on gastric and peritoneal tumors, surgical oncology, and nutrition, Qun Zhao’s work aligns with impactful research that directly benefits patients and advances medical science.

✅ Editorial and Research Contributions: While specific journal publications, patents, or citation indices are not provided, editorial appointments and professional memberships suggest recognition by the academic community.

✅ Potential for Industry Impact: If consultancy or industry projects exist (to be detailed), they could indicate translational research, bridging academia with practical medical applications.

Education 🎓

Dr. Qun Zhao completed his medical education and specialized training in surgical oncology at renowned institutions. His academic journey has been marked by a commitment to continuous learning and specialization in gastrointestinal malignancies and surgical techniques.

Experience 🌟

Dr. Zhao holds a prominent position in the medical field, serving in various leadership roles, including the Standing Committee memberships in multiple prestigious oncology and surgical nutrition groups. His expertise extends across peritoneal tumor management, gastric cancer treatment, and gastrointestinal mesenchymal tumors. His clinical acumen and research contributions have had a significant impact on cancer treatment methodologies.

Research Interests On Medicine 🔬

Dr. Zhao’s research focuses on innovative surgical techniques, tumor nutrition, and multimodal cancer treatment strategies. His work aims to improve patient outcomes through targeted therapies and advanced surgical interventions. His ongoing projects include groundbreaking research in peritoneal metastases and gastrointestinal stromal tumors.

Awards 🏆

Dr. Zhao has been recognized for his outstanding contributions to surgical oncology and cancer research. His accolades include awards from national and international oncology societies for his pioneering work in gastric and peritoneal tumors.

Publications 📚

Dr. Zhao has authored numerous peer-reviewed articles in high-impact journals. Some of his key publications include:

  • Pioneering case: Robot-assisted remote radical distal gastrectomy for gastric cancer based on 5G communication technology
    • Authors: Honghai Guo, Yuan Tian, Jia Shi, Peigang Yang, Jiaxuan Yang, Pingan Ding, Xuefeng Zhao, Zhidong Zhang, Qun Zhao
    • Publication Year: 2024
    • DOI: 10.1016/j.isurg.2024.01.004
  • Comment on ‘Hand grip strength‐based cachexia index as a predictor of cancer cachexia and prognosis in patients with cancer’ by Xie et al.
    • Authors: Ping’an Ding, Jiaxiang Wu, Haotian Wu, Chenyu Sun, Muzi Meng, Scott Lowe, Yuan Tian, Honghai Guo, Lingjiao Meng, Qun Zhao
    • Publication Year: 2023
    • DOI: 10.1002/jcsm.13298
  • Comment on: ‘Triceps skinfold‐albumin index significantly predicts the prognosis of cancer cachexia: A multicentre cohort study’ by Yin et al.
    • Authors: Ping’an Ding, Haotian Wu, Jiaxiang Wu, Chenyu Sun, Muzi Meng, Peigang Yang, Yang Liu, Lingjiao Meng, Qun Zhao
    • Publication Year: 2023
    • DOI: 10.1002/jcsm.13304
  • Safety and efficacy of carbon nanoparticle suspension injection and indocyanine green tracer-guided lymph node dissection during robotic distal gastrectomy in patients with gastric cancer
    • Authors: Yuan Tian, Yecheng Lin, Honghai Guo, Yiyang Hu, Yong Li, Liqiao Fan, Xuefeng Zhao, Dong Wang, Bibo Tan, Qun Zhao
    • Publication Year: 2022
    • DOI: 10.1007/s00464-021-08630-8
  • Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
    • Authors: Yuan Tian, Qun Zhao, Yong Li, Liqiao Fan, Zhidong Zhang, Xuefeng Zhao, Bibo Tan, Dong Wang, Peigang Yang, Nicola Silvestris
    • Publication Year: 2021
    • DOI: 10.1155/2021/5590626

Conclusion 🥇

Dr. Qun Zhao’s dedication to oncology research and patient care continues to influence the medical community. His innovative approaches in surgery and therapeutic nutrition play a pivotal role in advancing cancer treatment. His contributions, both in research and clinical practice, underscore his commitment to improving healthcare outcomes globally.